Ignite Creation Date:
2025-12-24 @ 11:57 PM
Ignite Modification Date:
2025-12-30 @ 10:53 AM
Study NCT ID:
NCT06573151
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-08-27
First Post:
2024-08-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
Sponsor:
Ruijin Hospital
Organization:
Study Overview
Official Title:
The Efficacy and Safety of Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in the Treatment of Relapsed or Refractory Natural Killer / T-cell Lymphoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody and P-GemOx in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.
Detailed Description:
This study aims to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus P-GemOx in relapsed or refractory NKTCL and find the optimal treatment regimen for patients with relapsed refractory NKTCL.
Patients receive 3 cycles of Selinexor, anti-PD-1 antibody plus P-GemOx, and then PET evaluation.
Patients receive 3 cycles of Selinexor, anti-PD-1 antibody plus P-GemOx, and then PET evaluation.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: